BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2019

View Archived Issues

A11 Mb-IRDye800CW is a promising new probe for real-time fluorescence imaging in prostate cancer

Read More

Alios BioPharma presents first-in-human data for AL-794

Read More

FEN1 and APEX2 as potential new targets in BRCA2-mutant tumors

Read More

FDA clears IND application for FT-516 cell therapy derived from an engineered pluripotent stem cell

Read More

First mouse kidneys grown from mouse stem cells in rats

Read More

Recida Therapeutics launches to develop lead program, RC-01

Read More

AAV9 vector encoding modified HEXB shows promise in vivo for Tay-Sachs disease

Read More

China's NMPA clears IND for bispecific antibody IBI-318

Read More

Targeting NRAS activator STK19 blocks melanocyte malignant transformation and melanoma growth

Read More

Interim data presented from first-in-human study of AT-GAA in patients with Pompe disease

Read More

Sanofi Genzyme presents long-term safety data for avalglucosidase alfa in Pompe disease

Read More

iVeena initiates phase I/IIa study of IVMED-80

Read More

Preliminary data presented from phase II study of MGTA-456 in inherited metabolic disorders

Read More

DSMB completes its third review of phase I/IIa study of VBI-1901 in recurrent GBM

Read More

Interim phase IIb data shows promising signs of clinical benefit for MDNA-55 in rGBM

Read More

New phase III study of empagliflozin assesses cardio-renal outcomes in chronic kidney disease

Read More

Moleculin's third drug candidate approved to enter clinical testing

Read More

Antidote Therapeutics to collaborate with NCI on development of ATI-1013

Read More

Ligand Pharmaceuticals enters OmniAb collaboration with Genagon Therapeutics

Read More

2-AG is a predictor of poor outcome in patients with aSAH

Read More

FDA clears IND for phase II study of Pulmazole in allergic bronchopulmonary aspergillosis

Read More

AbbVie patents lysophospholipid S1P5 receptor agonists

Read More

Phenex-FXR presents modulators of oxysterol receptors

Read More

Improved liver-targeted AAV gene therapy has long-lasting effects in Fabry disease model

Read More

Bayer and DKFZ jointly identify MAP4K1 inhibitors

Read More

Selection Biosciences divulges new 3-quinuclidone compounds

Read More

Chinese researchers disclose EGFR inhibitors

Read More

Sanofi to seek new partner for ophthalmology gene therapies SAR-422459 and SAR-421869

Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 17, 2026
  • First-in-class POLG activator restores mtDNA across mutations

    BioWorld Science
    Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing